S1P4 Inhibitors
1 drugsAbout S1P4
S1P4 is a G protein-coupled receptor (GPCR) that regulates immune cell trafficking and function within the S1P receptor family. It has emerged as a compelling target in immunology due to its role in modulating immune responses.
Currently, there is no genetic evidence directly linking S1P4 to specific diseases. However, the approval of VELSIPITY validates S1P4 as a therapeutic target in immunology.
S1P4 is targeted by one FDA-approved drug, VELSIPITY (Pfizer), a small molecule used in immunology. Pfizer is the only company with an approved S1P4-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Colitis, Ulcerative with only 1 trials.
Top Drugs
Pfizer is the only company with an approved drug targeting S1P4.
The market is highly concentrated, suggesting high barriers to entry or limited interest.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets S1P4, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel biologics.
Clinical Trials 46 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 8 | 1 | 3 | 89% |
| Phase 2 | 22 | 15 | 4 | 3 | 79% |
| Phase 3 | 8 | 6 | 1 | 1 | 86% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2023 - 2023)
VELSIPITY was the first and most recent drug approved in 2023, representing a 1-year span.
The recent approval suggests potential for further development, but also early market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 29 clinical trials targeting S1P4.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities